Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability

English version České info

Ebola virus, a member of the Filoviridae family, causes lethal hemorrhagic fever in man and primates, displaying up to 90% mortality rates. Viral infection is typified by an excessive systemic inflammatory response resembling septic shock. It also damages endothelial cells and creates difficulty in coagulation, ultimately leading to haemorrhaging, organ failure and death. A unique feature of EBOV is that following infection high amounts of truncated surface GP, named shed GP, are released from infected cells and are detected in the blood of patients and experimentally infected animals. However the role of shed GP in virus replication and pathogenicity is not yet clearly defined. Here we show that shed GP released from virus-infected cells binds and activates non-infected DCs and macrophages causing the massive release of pro- and anti-inflammatory cytokines and also affects vascular permeability. These activities could be at the heart of the excessive and dysregulated inflammatory host reactions to infection and thus contribute to high virus pathogenicity.

Vyšlo v časopise: Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability. PLoS Pathog 10(11): e32767. doi:10.1371/journal.ppat.1004509
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004509

Souhrn

Zdroje

1. BaizeS, PannetierD, OestereichL, RiegerT, KoivoguiL, et al. (2014) Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report. N Engl J Med

2. Du ToitA (2014) Ebola virus in West Africa. Nat Rev Microbiol 12: 312.

3. LigonBL (2005) Outbreak of Marburg hemorrhagic fever in Angola: a review of the history of the disease and its biological aspects. Semin Pediatr Infect Dis 16: 219–224.

4. MohamadzadehM (2009) Potential factors induced by filoviruses that lead to immune supression. Curr Mol Med 9: 174–185.

5. MahantyS, BrayM (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4: 487–498.

6. MehediM, GrosethA, FeldmannH, EbiharaH (2011) Clinical aspects of Marburg hemorrhagic fever. Future Virol 6: 1091–1106.

7. FeldmannH, NicholST, KlenkHD, PetersCJ, SanchezA (1994) Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199: 469–473.

8. Feldmann H, Klenk HD, Sanchez A (1993) Molecular biology and evolution of filoviruses. Arch Virol Suppl 7: 81–100.

9. SanchezA, KileyMP, HollowayBP, AuperinDD (1993) Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29: 215–240.

10. VolchkovaVA, FeldmannH, KlenkHD, VolchkovVE (1998) The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250: 408–414.

11. SanchezA, TrappierSG, MahyBW, PetersCJ, NicholST (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93: 3602–3607.

12. VolchkovVE, FeldmannH, VolchkovaVA, KlenkHD (1998) Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95: 5762–5767.

13. FalzaranoD, KrokhinO, Wahl-JensenV, SeebachJ, WolfK, et al. (2006) Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem 7: 1605–1611.

14. VolchkovaVA, KlenkHD, VolchkovVE (1999) Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 265: 164–171.

15. VolchkovVE (1999) Processing of the Ebola virus glycoprotein. Curr Top Microbiol Immunol 235: 35–47.

16. JeffersSA, SandersDA, SanchezA (2002) Covalent modifications of the ebola virus glycoprotein. J Virol 76: 12463–12472.

17. Alazard-DanyN, VolchkovaV, ReynardO, CarbonnelleC, DolnikO, et al. (2006) Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 87: 1247–1257.

18. LeeJE, FuscoML, HessellAJ, OswaldWB, BurtonDR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177–182.

19. MartinezO, TantralL, MulherkarN, ChandranK, BaslerCF (2011) Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis 204 Suppl 3S825–832.

20. ReynardO, BorowiakM, VolchkovaVA, DelpeutS, MateoM, et al. (2009) Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 83: 9596–9601.

21. DolnikO, VolchkovaV, GartenW, CarbonnelleC, BeckerS, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175–2184.

22. VolchkovVE, BeckerS, VolchkovaVA, TernovojVA, KotovAN, et al. (1995) GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214: 421–430.

23. ZakiSR, GoldsmithCS (1999) Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 235: 97–116.

24. FeldmannH, GeisbertTW (2011) Ebola haemorrhagic fever. Lancet 377: 849–862.

25. TakadaA (2012) Filovirus tropism: cellular molecules for viral entry. Front Microbiol 3: 34.

26. BrayM, GeisbertTW (2005) Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37: 1560–1566.

27. MartinezO, JohnsonJC, HonkoA, YenB, ShabmanRS, et al. (2013) Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol 87: 3801–3814.

28. GuptaM, MahantyS, AhmedR, RollinPE (2001) Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284: 20–25.

29. MahantyS, HutchinsonK, AgarwalS, McRaeM, RollinPE, et al. (2003) Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170: 2797–2801.

30. LubakiNM, IlinykhP, PietzschC, TigabuB, FreibergAN, et al. (2013) The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol 87: 7471–7485.

31. Wahl-JensenV, KurzS, FeldmannF, BuehlerLK, KindrachukJ, et al. (2011) Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis 5: e1359.

32. Wahl-JensenV, KurzSK, HazeltonPR, SchnittlerHJ, StroherU, et al. (2005) Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 79: 2413–2419.

33. RubinsKH, HensleyLE, Wahl-JensenV, Daddario DiCaprioKM, YoungHA, et al. (2007) The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 8: R174.

34. CaescuCI, JeschkeGR, TurkBE (2009) Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J 424: 79–88.

35. YangZY, DuckersHJ, SullivanNJ, SanchezA, NabelEG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6: 886–889.

36. ChanSY, MaMC, GoldsmithMA (2000) Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81: 2155–2159.

37. VolchkovVE, ChepurnovAA, VolchkovaVA, TernovojVA, KlenkHD (2000) Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277: 147–155.

38. EzekowitzRA (2003) Role of the mannose-binding lectin in innate immunity. J Infect Dis 187 Suppl 2S335–339.

39. ThielS, JensenL, DegnSE, NielsenHJ, GalP, et al. (2012) Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components. Clin Exp Immunol 169: 38–48.

40. KilpatrickDC (2002) Mannan-binding lectin and its role in innate immunity. Transfus Med 12: 335–352.

41. TakahashiK, IpWE, MichelowIC, EzekowitzRA (2006) The mannose-binding lectin: a prototypic pattern recognition molecule. Curr Opin Immunol 18: 16–23.

42. MichelowIC, DongM, MungallBA, YantoscaLM, LearC, et al. (2010) A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J Biol Chem 285: 24729–24739.

43. BrudnerM, KarpelM, LearC, ChenL, YantoscaLM, et al. (2013) Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One 8: e60838.

44. FuchsA, PintoAK, SchwaebleWJ, DiamondMS (2011) The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology 412: 101–109.

45. FuchsA, LinTY, BeasleyDW, StoverCM, SchwaebleWJ, et al. (2010) Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 8: 186–195.

46. JiX, OlingerGG, ArisS, ChenY, GewurzH, et al. (2005) Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 86: 2535–2542.

47. MichelowIC, LearC, ScullyC, PrugarLI, LongleyCB, et al. (2011) High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis 203: 175–179.

48. DubeD, SchornbergKL, ShoemakerCJ, DelosSE, StantchevTS, et al. (2010) Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A 107: 16637–16642.

49. MarziA, MollerP, HannaSL, HarrerT, EisemannJ, et al. (2007) Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis 196 Suppl 2S237–246.

50. Babovic-VuksanovicD, SnowK, TenRM (1999) Mannose-binding lectin (MBL) deficiency. Variant alleles in a midwestern population of the United States. Ann Allergy Asthma Immunol 82: 134–141, 134-138-141 quiz 142–133..

51. GarredP, LarsenF, SeyfarthJ, FujitaR, MadsenHO (2006) Mannose-binding lectin and its genetic variants. Genes Immun 7: 85–94.

52. OkumuraA, PithaPM, YoshimuraA, HartyRN (2010) Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol 84: 27–33.

53. Ganley-LealLM, LiangY, Jagannathan-BogdanM, FarrayeFA, NikolajczykBS (2010) Differential regulation of TLR4 expression in human B cells and monocytes. Mol Immunol 48: 82–88.

54. MuzioM, BosisioD, PolentaruttiN, D'AmicoG, StoppacciaroA, et al. (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164: 5998–6004.

55. ZaremberKA, GodowskiPJ (2002) Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168: 554–561.

56. ShimizuT, NishitaniC, MitsuzawaH, ArikiS, TakahashiM, et al. (2009) Mannose binding lectin and lung collectins interact with Toll-like receptor 4 and MD-2 by different mechanisms. Biochim Biophys Acta 1790: 1705–1710.

57. WangM, ChenY, ZhangY, ZhangL, LuX, et al. (2011) Mannan-binding lectin directly interacts with Toll-like receptor 4 and suppresses lipopolysaccharide-induced inflammatory cytokine secretion from THP-1 cells. Cell Mol Immunol 8: 265–275.

58. MaYJ, KangHJ, KimJY, GarredP, LeeMS, et al. (2013) Mouse mannose-binding lectin-A and ficolin-A inhibit lipopolysaccharide-mediated pro-inflammatory responses on mast cells. BMB Rep 46: 376–381.

59. MuzioM, PolentaruttiN, BosisioD, PrahladanMK, MantovaniA (2000) Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 67: 450–456.

60. ZhangG, GhoshS (2000) Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 6: 453–457.

61. BrightbillHD, ModlinRL (2000) Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology 101: 1–10.

62. BaizeS, LeroyEM, GeorgesAJ, Georges-CourbotMC, CapronM, et al. (2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128: 163–168.

63. HensleyLE, YoungHA, JahrlingPB, GeisbertTW (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80: 169–179.

64. BeutlerB (2002) Toll-like receptors: how they work and what they do. Curr Opin Hematol 9: 2–10.

65. StroherU, WestE, BuganyH, KlenkHD, SchnittlerHJ, et al. (2001) Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75: 11025–11033.

66. RyabchikovaEI, KolesnikovaLV, NetesovSV (1999) Animal pathology of filoviral infections. Curr Top Microbiol Immunol 235: 145–173.

67. Wahl-JensenVM, AfanasievaTA, SeebachJ, StroherU, FeldmannH, et al. (2005) Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 79: 10442–10450.

68. GeisbertTW, YoungHA, JahrlingPB, DavisKJ, LarsenT, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163: 2371–2382.

69. HensleyLE, GeisbertTW (2005) The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 94: 254–261.

70. RoyallJA, BerkowRL, BeckmanJS, CunninghamMK, MatalonS, et al. (1989) Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 257: L399–410.

71. WauquierN, BecquartP, PadillaC, BaizeS, LeroyEM (2010) Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 4

72. CillonizC, EbiharaH, NiC, NeumannG, KorthMJ, et al. (2011) Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J Virol 85: 9060–9068.

73. GrosethA, MarziA, HoenenT, HerwigA, GardnerD, et al. (2012) The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog 8: e1002847.

74. XieXH, LiuEM, YangXQ, LawHK, LiX, et al. (2008) [Toll-like receptor 4 expression and function of respiratory syncytial virus-infected airway epithelial cells]. Zhonghua Jie He He Hu Xi Za Zhi 31: 213–217.

75. TalG, MandelbergA, DalalI, CesarK, SomekhE, et al. (2004) Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189: 2057–2063.

76. HaynesLM, MooreDD, Kurt-JonesEA, FinbergRW, AndersonLJ, et al. (2001) Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75: 10730–10737.

77. BurzynD, RassaJC, KimD, NepomnaschyI, RossSR, et al. (2004) Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol 78: 576–584.

78. BukreyevA, YangL, FrickeJ, ChengL, WardJM, et al. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191–12204.

79. DaubeufB, MathisonJ, SpillerS, HuguesS, HerrenS, et al. (2007) TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 179: 6107–6114.

80. MoeJB, LambertRD, LuptonHW (1981) Plaque assay for Ebola virus. J Clin Microbiol 13: 791–793.

81. VolchkovVE, VolchkovaVA, MuhlbergerE, KolesnikovaLV, WeikM, et al. (2001) Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291: 1965–1969.

82. MateoM, CarbonnelleC, ReynardO, KolesnikovaL, NemirovK, et al. (2011) VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J Infect Dis 204 Suppl 3S1011–1020.